Unveiling CXCR2 as a promising therapeutic target in renal cell carcinoma: exploring the immunotherapeutic paradigm shift through its inhibition by RCT001

CONCLUSIONS: RCT001, by inhibiting CXCR2 through its unique mechanism, effectively suppresses ccRCC cell proliferation, angiogenesis, and M2 macrophage polarization. This optimization potentiates the efficacy of immunotherapy and holds promise for significantly improving the survival prospects of metastatic ccRCC patients.PMID:38504270 | DOI:10.1186/s13046-024-02984-2

Source: Cell Research - March 20, 2024 Category: Cytology Authors: Christopher Montemagno Arnaud Jacquel Charlotte Pandiani Olivia Rastoin Rosie Dawaliby Thomas Schmitt Maxence Bourgoin H éliciane Palenzuela Anne-Laure Rossi Damien Ambrosetti Jerome Durivault Frederic Luciano Delphine Borchiellini Julie Le Du Leticia Ch Source Type: research